From Lab to Deal-Making: The Rise of the Chief Business Officer in Sci-Tech Startups

“BD should act as the company’s antennae, constantly exploring and sensing the external environment, feeding information back to the central hub, and dynamically adjusting the company’s market positioning based on internal conditions. This is a highly creative role, which is precisely what distinguishes it from the stereotypical perception of sales.”

Many companies spun off from scientific research achievements initially began as mere concepts:

The Commercial Viability of an Early-Stage Scientific Concept.

The survival and growth of these startups depend more on the team—specifically, the creativity of scientists and other founding members—than on the quality of the underlying scientific concepts.

In previous articles, we have extensively discussed the diverse roles of scientists as the technological core of companies and how they guide teams through the treacherous “Valley of Death.” Today, we begin to focus on another group within the core team: those who lead companies out of the Valley of Death.Striving for the PeakC-Level (i.e., top-level executives with Chief titles within an organization)Members。

Translating scientific concepts into products requires capital—substantial capital.

Once scientists have completed the initial proof of concept, the founding team must begin asking themselves:

1. Who is responsible for establishing relationships with clients or partners?

2. Which potential relationships contribute to the company’s development, or possess technologies, skills, or intellectual property that are complementary to the company?

3. Who is closely monitoring industry developments, gaining insight into trending narratives, or has firsthand knowledge of which major companies are about to start seeking similar products?

Of course, there is no need to worry if these questions cannot be answered. The team can begin considering the inclusion of a Chief Business Officer (CBO) at an appropriate time.

Very early-stage companies are not in a hurry to hire a Chief Business Officer (CBO). At this stage, deals or project collaborations can be fully facilitated and assisted by the founding team (typically scientists and founders) or investors.

Typically, companies canComplete proof of concept, establish a strong intellectual property moat, and secure funding for the next stage.Afterward, proceed with the search for an outstanding Head of Business Development.

The emergence of CBOs also requires consideration of a company’s “momentum” and “model.” After all,The energy and momentum required for the company’s early-stage development are inconsistent with its positioning regarding the competitive landscape and potential customers in its medium- to long-term strategic planning.。

If we distill it down to its essence, a benchmark CBO is actually responsible for only one thing:Maximize the value of the company’s technology through external collaborations to address targeted market demands.

Based on this, the approach that can maximize the company’s technological value is:

1. Clearly Defined Milestone Goals

2. Consideration of risks and investment returns for all parties

3. Long-term Strategic Vision and Planning

4. Adaptability to Changes in the Market Environment

As a result of this complexity, negotiations for any business development (BD) partnership involve multi-member teams from two or more parties, rather than individual representatives.But the key point is that the CBO must lead the team and serve as the primary contact for negotiations.。

A typical sign that a business development (BD) partnership is on the verge of collapse is when various one-on-one communications begin to emerge among different combinations of individuals across the respective teams.Therefore, a key characteristic of CBO is its ability to guide negotiations in a summary manner.

Another important attribute of a CBO is the ability to understand the potential value of technologies or products.. The value here lies in mutual benefit for both parties, rather than solely for one’s own company. This is because a significant proportion of business development (BD) collaborations are conducted through patent licensing and technical cooperation. Moreover, an initial collaboration has a high likelihood of serving as the foundation for a long-term, amicable partnership.

How to resist the temptation of high premiums from “one-off” collaborations during negotiations and instead factor in the counterparty’s long-term benefits is a testament to how a Chief Business Officer (CBO) can maximize the value of technology.

This trait tests the CBO’s multifaceted understanding of technology, R&D, product, marketing, and patents, and most importantly:How to Translate Intangible Value into Tangible Terms at the Negotiating Table。

So, what does a real-world CBO look like?

Stephanie Bewick is an industry veteran with nearly 20 years of experience in business development (BD). After leaving academia, she has dedicated herself to BD as an external consultant and corporate executive. She has previously held positions at Summit Therapeutics, Destiny Pharma, and Accession Therapeutics, among others. Notably, Summit Therapeutics recently finalized a $5 billion collaboration agreement with Akeso Inc.

Her series of questions regarding the CBO role can provide entrepreneurs and scientists with a refreshed understanding of this position.

Here is the condensed version:

1. Passionate about science while yearning for the world beyond the laboratory

2. Closely track unmet clinical needs and the targeted initiatives of major pharmaceutical companies

3. Align commercialization requirements with R&D and clinical teams

4. Remember: Negotiate milestones for early-stage projects, and upfront payments for mature projects.

5. Able to understand what other C-level executives are discussing

6. Enables other C-level executives to understand what you are saying

Detailed Version:

What led you to pursue a career in business development and become a Chief Business Officer?

“My appointment as CBO was a natural progression after many years in business development.

Prior to leaving academia, I was engaged in neuroscience-related research. While I greatly enjoyed the process of scientific exploration, I found that I did not favor long-term bench work; therefore, I decided to transition into the biotech industry to pursue a career in Business Development (BD).

In many large corporations, business development (BD) may be perceived as sales. However, in biotech startups focused on developing therapeutic products, it actually involves extensive market analysis., investigate various diseases, determine the number of patients and unmet needs, and identify which companies are developing targeted products?”

What Is the Transition from Academia to Industry Like?

“For scientists in academia, you might think, “I want to pursue this research direction because it’s interesting.” In the corporate world, however, the more common consideration is whether there is market demand for it.

As CBO, the message I aim to instill in the R&D team is: Do you see an opportunity here, and is it commercially viable? In the UK, most biotech companies do not sell products directly; instead, they rely on development partnerships or licensing deals with large pharmaceutical companies, which then bring the products to market.

What I have learned from my previous work is that I must persuade the R&D team to consider commercialization issues, or convince the clinical team, which does not take reimbursement into account.We all need to think with a commercial mindset. This is something you must always keep in mind. Without developing the right products, we cannot provide quality services to patients.”

Are there differences in your negotiations between early-stage and mature projects?

“In early-stage projects, due to the high likelihood of product failure, substantial upfront payments are unlikely; therefore, it is justified to secure high-proportion milestone payments at subsequent value inflection points.

For mature projects, you may have already advanced the project to Phase II clinical trials. Many R&D risks have been mitigated, and the likelihood of successfully entering Phase III clinical trials is higher; therefore, you can anticipate a higher upfront payment.”

How does the CBO typically collaborate with other C-level executives?

“As the CBO of an early-stage company, you need to be able to communicate with other C-level executives. The role of a CBO is not just about making deals. A CBO must ensure that the company understands why they are doing what they do, and must interact with all functions including clinical, compliance, CMO, CSO, CFO, etc.

You need to patiently and effectively convey your ideas in a manner that is understandable to the other party, which requires you to have an understanding of and alignment with the needs of each sector.”

What Key Qualifications Should a CBO Possess?

“I believe it is the ability to take a holistic view. It may sound like a cliché, but that is indeed the case in reality.

You don’t need to be a leading expert in the field or hold a CFA designation, but you must be able to discuss R&D using the language of scientists and explain concepts to investors in layman’s terms.”

It is not difficult to draw the conclusion,A good BD professional needs to possess sufficient cross-disciplinary knowledge and problem-solving skills.It is no exaggeration to call them a hexagonal warrior.

Sound strategic thinking is essential, but implementing these strategies requires tactical execution grounded in negotiation skills and relationship building. The tangible embodiment of business development (BD) outcomes—cooperation agreements—relies heavily on legal acumen. Stripping away these layers, the core foundation remains the underlying scientific research and technology upon which the company’s survival depends.

If all of this were shattered,Break down into the smallest units that can be specifically understood, we can see the following expressions:

1. Planning to Achieve Revenue Targets

2. Identify Additional Revenue Streams from the Company’s Existing Resources

3. Rapidly achieve an in-depth understanding of the company’s products and services

4. Identify new business opportunities and negotiate terms

5. Understand customer needs and establish a well-founded collaboration framework

6. Dynamically Align Partner Interests with Corporate Strategy

7. Identify Partnership and M&A Opportunities for Corporate Value Enhancement

8. Maintain good working relationships with R&D and operations teams

9. Maintain good and effective communication with the project leader

10. Enhance and maintain the company’s image in the eyes of potential partners

These minimal units defining CBOs are believed to hold certain reference value for both researchers seeking to transition into new roles and founders looking to bring BD professionals on board.

Reference Article:

Business Development in Biotech – a competitive advantage?

Chief Business Officers: Shedding Light on Biotech’s Dealmakers